Germany has signed contracts with Celonic AG and four other partners to secure the long-term supply of vaccines in Germany against Covid-19 and other pandemics.   Celonic will provide the capacity and the expertise for the production of protein-based vaccines at its Heidelberg site at least until 2029. If required, production of up to 80 million doses per year can begin immediately. Celonic will thus become an important part of pandemic preparedness in Germany. About Celonic Celonic runs ...